News

Pharma’s Almanac || What do you consider the biggest challenge that the pharma/biopharma industry currently faces?

Marilyn Matz, Chief Executive Officer and Co-Founder, Paradigm4 “Genomics’ role in the life science vision “is only as credible as its implementation,”

whitepages icon x

IPI || Why the right approach to data management will enable the potential of small-molecule RNA sodifiers as drug targets to be fulfilled

Over the past 5 decades or so, the growing understanding that RNA can influence protein function through routes other than direct translation has opened the prospect of discovering small molecules for tackling diseases in novel ways.

whitepages icon x

Biocompare || Introduction to Spatial Metabolomics

Metabolomics—often referred to as the youngest of the omics—provides key insight into phenotype. However, bulk metabolomics requires the homogenization of the sample and is thus unable to discern metabolic differences at a cellular level.

whitepages icon x

Pharma’s Almanac | What do you think most differentiates the U.S. pharma/biopharma industry or the market?

Paradigm4’s Marilyn Matz reflects on the understanding complex biological phenomena has required concurrent advances in experimental methods and computing power.